GlassScriptPhysician profile
William K Denton
NPI 1417041690
$2,790.60
in general payments reported to CMS, 2019-2025
38 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $284 · 2021: $635 · 2022: $344 · 2023: $722 · 2024: $348 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.89 |
| Education | $285.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $323.49 | 2019-2023 | Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $278.83 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $206.43 | 2019-2023 | |
| Inari Medical, INC. | $200.00 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lilly USA, LLC | $180.93 | 2020-2024 | Mounjaro, Zepbound |
| Amgen INC. | $179.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $147.34 | 2020-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $108.05 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $107.49 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $97.13 | 2020-2023 | Rexulti |
| Novo Nordisk INC | $92.60 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.44 | 2022-2024 | Ofev, Jardiance |
| Sun Pharmaceutical Industries INC. | $72.73 | 2020-2022 | |
| Intuitive Surgical, INC. | $62.87 | 2023 | Da Vinci Surgical System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.39 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $53.23 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Shield Therapeutics INC | $52.73 | 2023 | Accrufer |
| Esperion Therapeutics, INC. | $42.69 | 2021-2022 | |
| Averitas Pharma INC. | $39.27 | 2023 | Qutenza |
| Smith+Nephew, INC. | $35.70 | 2022 | |
| Exact Sciences Corporation | $35.16 | 2023-2024 | Cologuard Collection Kit |
| Ardelyx, INC. | $34.65 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $34.31 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Vertex Pharmaceuticals Incorporated | $29.74 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.25 | 2022-2024 | Xifaxan, Trulance |
| Abbvie INC. | $24.88 | 2021-2023 | Linzess |
| Amarin Pharma, INC. | $23.76 | 2020 | |
| Xeris Pharmaceuticals, INC. | $20.75 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.63 | 2023 | Givlaari |
| Biohaven Pharmaceutical Holding Company LTD. | $18.84 | 2022 | |
| Capsovision, INC. | $17.40 | 2023 | Capsocam Plus |
| Solventum Corporation | $16.12 | 2025 | Prevena, Activ.A.C. |
| Sanofi-Aventis U.S. LLC | $12.39 | 2022 | |
| Pfizer INC. | $12.11 | 2020 | |
| Genentech USA, INC. | $11.96 | 2020 | |
| Chiesi USA, INC. | $11.71 | 2021 | |
| Corium, LLC | $11.43 | 2023 | Azstarys |
| Nestle Healthcare Nutrition INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Denton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.